Lunit Partners with SITC to Launch Exclusive Research Program Featuring Advanced AI Technology for SITC Members

Lunit Partners with SITC to Launch Exclusive Research Program Featuring Advanced AI Technology for SITC Members

Lunit SCOPE® IO now available to SITC members for AI-powered TME profiling, in a collaborative effort to advance cancer immunotherapy SEOUL, South Korea, Feb. 3, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions...

Hanmi Pharmaceutical and Beijing Hanmi Progress Clinical Trials of Co-developed BH3120 as a Next-Generation Cancer Immunotherapy

Hanmi Pharmaceutical and Beijing Hanmi Progress Clinical Trials of Co-developed BH3120 as a Next-Generation Cancer Immunotherapy

Hanmi unveils tiral in progress poster on BH3120 at the Society for Immunotherapy of Cancer (SITC) in the U.S. Phase 1 trial is progressing smoothly, with no dose-limiting toxicity observed Phase 1 trial evaluating the combination of BH3120 and...

menu
menu